Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer directly owned 940,392 shares of the company's stock, valued at approximately $21,177,627.84. This represents a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Samuel Kintz also recently made the following trade(s):
- On Tuesday, June 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.18, for a total transaction of $277,250.00.
- On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.05, for a total transaction of $150,375.00.
- On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.49, for a total value of $82,450.00.
- On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.08, for a total value of $107,026.40.
Enliven Therapeutics Price Performance
NASDAQ ELVN traded up $0.70 on Wednesday, reaching $22.26. The company had a trading volume of 48,821 shares, compared to its average volume of 306,902. The firm has a market capitalization of $1.09 billion, a PE ratio of -11.55 and a beta of 0.83. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The firm has a 50-day moving average of $20.16 and a 200-day moving average of $20.23.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Analyst Ratings Changes
ELVN has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Robert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, HC Wainwright boosted their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Enliven Therapeutics presently has an average rating of "Buy" and an average price target of $41.20.
Check Out Our Latest Report on Enliven Therapeutics
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors have recently made changes to their positions in ELVN. Ameriprise Financial Inc. acquired a new stake in Enliven Therapeutics in the fourth quarter worth $789,000. Millennium Management LLC boosted its stake in Enliven Therapeutics by 108.6% during the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after buying an additional 26,449 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after buying an additional 17,546 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Enliven Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after purchasing an additional 2,466 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Enliven Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock worth $5,892,000 after acquiring an additional 6,611 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More

Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.